Frank Rimerman Advisors’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.18M Buy
5,216
+19
+0.4% +$4.03K 0.07% 221
2026
Q2
$1.12M Buy
5,197
+3
+0.1% +$574 0.06% 225
2026
Q1
$952K Buy
5,194
+12
+0.2% +$2.21K 0.06% 250
2025
Q4
$912K Buy
5,182
+1
+0% +$163 0.06% 247
2025
Q3
$726K Sell
5,181
-187
-3% -$25.3K 0.05% 287
2025
Q2
$674K Buy
+5,368
New +$669K 0.05% 289
2025
Q1
– Sell
-3,337
Closed -$510K – 519
2024
Q4
$510K Buy
+3,337
New +$563K 0.04% 305
2024
Q3
– Sell
-1,179
Closed -$273K – 531
2024
Q2
$273K Buy
+1,179
New +$256K 0.02% 465
2024
Q1
– Sell
-49
Closed -$12.7K – 338
2023
Q4
$12.7K Buy
+49
New +$12K ﹤0.01% 163

Other funds holding BIIB

Frank Rimerman Advisors's BIIB Position: Q3 2026 in Review

Frank Rimerman Advisors increased its Biogen (BIIB) stake by 0.37% in Q3 2026, buying an estimated $4.03K and bringing the position to 5,216 shares worth $1.18M. The position accounts for 0.07% of the portfolio, ranked #221.

Frank Rimerman Advisors first reported a position in BIIB in Q4 2023 and has held it in 9 quarters since. 1,062 funds tracked by Wall St. Rank hold BIIB as of Q3 2026.

  • Frank Rimerman Advisors held 5,216 shares of Biogen worth $1.18M as of Q3 2026.
  • Frank Rimerman Advisors bought 19 Biogen shares in Q3 2026, an estimated $4.03K.
  • Biogen made up 0.07% of Frank Rimerman Advisors's portfolio in Q3 2026, its #221 holding.
  • Frank Rimerman Advisors first reported a position in Biogen in Q4 2023 and has held it in 9 quarters since.
  • 1,062 funds tracked by Wall St. Rank held Biogen as of Q3 2026.

Based on Frank Rimerman Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.